Targeting neuroendocrine tumors with octreotide and lanreotide: Key points for clinical practice from NET specialists

•Two long-acting somatostatin analogs (SSA) are available in clinical practice for NET.•Octreotide and lanreotide are approved for clinical syndrome and tumor growth control.•However, some clinical indications of approved SSA remain controversial.•A group of NET-specialists, critically addressed ten challenging questions on SSA use.